Report
EUR 17.97 For Business Accounts Only

ValuEngine Rating and Forecast Report for LNTH

ValuEngine Rating and Forecast Report for LNTH
Underlying
Lantheus Holdings

Lantheus Holdings is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Clinicians use its imaging agents and products across a range of imaging modalities, including echocardiography and nuclear imaging. The company's commercial products are used by cardiologists, nuclear physicians, radiologists, internal medicine physicians, technologists and sonographers working in a variety of clinical settings. The company's products include DEFINITY, which is an ultrasound contrast agent, and Thallium TI 201, which is an injectable radiopharmaceutical imaging agent.

Provider
ValuEngine Inc
ValuEngine Inc

​ValuEngine Rating and Forecast Reports provide the most comprehensive and useful report available. ValuEngine's three models: Valuation Model, Forecast Model and Ratings Model are incorporated to give you a well-rounded analysis from three different perspectives. ValuEngine provides coverage of over 5300 US stocks (which includes over 800 ADRs), all of which are updated daily after US market close.

 

ResearchPool Subscriptions

Get the most out of your insights

Get in touch